Insomnia is highly prevalent, but only a third of patients with insomnia say they have talked about it with their primary care provider, either specifically or in the context of other problems. In this case-based activity, an expert in the field discusses how to do a thorough—but not unnecessarily thorough—workup, comorbidities to be aware of, the importance of appropriately defining the specific type of insomnia, and the roles of various therapies, including cognitive behavioral therapy, traditional pharmacologic agents, and newer options.
Interactive case study
After completing this activity, participants should be better able to:
- Recognize signs, symptoms, and risk factors that should trigger screening and more thorough questioning of patients for insomnia
- Assess comorbidities and causes of insomnia to inform treatment decisions based on guideline recommendations
- Discuss the safety, efficacy, and appropriate use of the newest class of pharmacologic agent, orexin receptor antagonists, for the treatment of insomnia
NPs and PAs
CNE Credit Designation Statement
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.00, which are eligible for 1.00 pharmacology credit
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Continuing Education Alliance and Boston University. Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until March 30, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA Planner: Mark Christiansen, PhD, PA-C, University of the Pacific, Sacramento, California
This activity was developed from a series of programs co-supported by educational grants from AbbVie Inc.; Eisai; Genentech; GlaxoSmithKline; Novo Nordisk Inc.; Sanofi Genzyme and Regeneron Pharmaceuticals; and Sunovion Pharmaceuticals Inc.
This activity is supported by an educational grant from Eisai.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the American Academy of Physician Assistants, Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Neubauer: consultant: Eisai.
Dr Christiansen has no relevant financial relationships to disclose.
The Planning Committee for this activity included Claire Murphy, MSN, NP-C, Carmela A. Townsend, DNP, MS/MBA, RN, Jason Worcester, MD, Jody Walker, MS, and Julie L. White, MS, of Boston University School of Medicine; Mark Christiansen, PhD, PA-C, University of the Pacific Sacramento; and Ruth Cohen and Craig Borders of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Review the content
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: March 31, 2020
Expiration date: March 30, 2021
Any internet connected computer or mobile device with any of the following browsers: Internet Explorer, Google Chrome, Mozilla Firefox, Safari.
© 2020 Practicing Clinicians Exchange. All Rights Reserved. 95319CPCE-7G